Merit Medical Systems (NASDAQ:MMSI – Get Free Report) and TearLab (OTCMKTS:TEAR – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.
This table compares Merit Medical Systems and TearLab’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Merit Medical Systems||7.48%||14.60%||9.87%|
Valuation & Earnings
This table compares Merit Medical Systems and TearLab’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Merit Medical Systems||$1.15 billion||3.43||$74.52 million||$1.56||43.99|
This is a summary of recent ratings and recommmendations for Merit Medical Systems and TearLab, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Merit Medical Systems||0||1||4||0||2.80|
Merit Medical Systems currently has a consensus price target of $87.83, indicating a potential upside of 28.00%. Given Merit Medical Systems’ higher possible upside, research analysts clearly believe Merit Medical Systems is more favorable than TearLab.
Insider & Institutional Ownership
93.2% of Merit Medical Systems shares are owned by institutional investors. 3.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 5.2% of TearLab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Merit Medical Systems beats TearLab on 7 of the 8 factors compared between the two stocks.
About Merit Medical Systems
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy. It operates in two segments, Cardiovascular and Endoscopy. The company provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate strictures; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.